Cell and Gene Therapies Seed Grant

Applications accepted for Track 1 (budget of $50,000) or Track 2 (budget of up to $25,000)

Cell and Gene Therapies projects will include the design, production, and characterization of AAV vectors for preclinical applications. Optionally, up to ten constructs may be produced at small scale, purified by chromatography methods, and analyzed for titer (vg ddPCR, capsid ELISA), purity (SDS-PAGE), potency (cell-based transduction assay), and genome integrity (alkaline gel) and % full capsid (ddPCR)

In-kind support will include access to the Cell and Gene Therapies laboratory for AAV design, production, purification, and analytical testing, including associated consumables. It will also include guidance and academic support from at least one member of the AAV Vector Manufacturing team.

Competitive projects will identify at least one graduate student or postdoctoral scholar who will devote 20% of their time in the Cell and Gene Therapies laboratory for vector design, production, purification and analytical testing.

Cell and Gene Therapies is led by Fabrizia Urbinati (urbinati@stanford.edu)